Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as SAM-531
PF-05212365 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PF-05212365 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| PF-05212365 | DRUG | Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1. |
Inclusion Criteria: * Healthy male and/or female subjects of nonchildbearing potential between the ages of 18 and 55 years, inclusive Exclusion Criteria: * Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiat...
PF-05212365 is an investigational small molecule developed by Pfizer, Inc. (NYSE: PFE). It has been studied in a Phase 1 clinical trial involving healthy adult volunteers in the United States. The specific disease indications for which it was being developed have not been publicly disclosed.
PF-05212365 is being developed by Pfizer, Inc., which trades on the New York Stock Exchange under the ticker PFE. Pfizer sponsored the Phase 1 study of the compound conducted in the United States.
PF-05212365 is in Phase 1 clinical development. It is an investigational small molecule that has not been approved by the FDA. One Phase 1 trial has been completed, and no active trials are currently listed.
PF-05212365 has been evaluated in one completed Phase 1 trial, NCT01253655, titled "To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding In Brain Using PET (Positron Emission Tomography) In Healthy Volunteers." The study enrolled 6 healthy adult volunteers in the United States and was uncontrolled.
The Phase 1 trial NCT01253655 was an uncontrolled study that enrolled 6 healthy volunteers aged 18 years and older in the United States. It used positron emission tomography (PET) to evaluate the relationship between plasma drug levels of PF-05212365 and receptor binding in the brain. The trial is completed.